Birch Capital Management LLC Has $272,000 Stock Holdings in Abbott Laboratories $ABT

Birch Capital Management LLC lessened its position in Abbott Laboratories (NYSE:ABT) by 41.6% during the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 2,000 shares of the healthcare product maker’s stock after selling 1,423 shares during the period. Birch Capital Management LLC’s holdings in Abbott Laboratories were worth $272,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Brighton Jones LLC raised its holdings in shares of Abbott Laboratories by 10.1% in the fourth quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock valued at $5,850,000 after buying an additional 4,755 shares during the last quarter. Wealthcare Advisory Partners LLC raised its holdings in shares of Abbott Laboratories by 8.4% in the first quarter. Wealthcare Advisory Partners LLC now owns 13,282 shares of the healthcare product maker’s stock valued at $1,762,000 after buying an additional 1,024 shares during the last quarter. GAMMA Investing LLC raised its holdings in shares of Abbott Laboratories by 17.0% in the first quarter. GAMMA Investing LLC now owns 38,467 shares of the healthcare product maker’s stock valued at $5,103,000 after buying an additional 5,590 shares during the last quarter. Integrated Advisors Network LLC raised its holdings in shares of Abbott Laboratories by 30.9% in the first quarter. Integrated Advisors Network LLC now owns 26,003 shares of the healthcare product maker’s stock valued at $3,449,000 after buying an additional 6,131 shares during the last quarter. Finally, Redhawk Wealth Advisors Inc. bought a new position in shares of Abbott Laboratories in the first quarter valued at about $297,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

Abbott Laboratories Stock Performance

Shares of ABT stock opened at $133.24 on Friday. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.82 and a quick ratio of 1.30. The stock has a market cap of $231.90 billion, a PE ratio of 16.70, a price-to-earnings-growth ratio of 2.55 and a beta of 0.69. The stock has a 50-day moving average of $132.44 and a 200-day moving average of $131.52. Abbott Laboratories has a one year low of $110.86 and a one year high of $141.23.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 EPS for the quarter, meeting analysts’ consensus estimates of $1.26. The company had revenue of $11.14 billion during the quarter, compared to analysts’ expectations of $11.01 billion. Abbott Laboratories had a return on equity of 18.32% and a net margin of 32.43%.Abbott Laboratories’s revenue was up 7.4% on a year-over-year basis. During the same period in the prior year, the business posted $1.14 EPS. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. As a group, sell-side analysts expect that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, November 17th. Investors of record on Wednesday, October 15th will be given a $0.59 dividend. The ex-dividend date is Wednesday, October 15th. This represents a $2.36 annualized dividend and a dividend yield of 1.8%. Abbott Laboratories’s payout ratio is currently 29.57%.

Insider Activity

In related news, CFO Philip P. Boudreau sold 5,550 shares of the business’s stock in a transaction that occurred on Friday, August 8th. The stock was sold at an average price of $134.55, for a total value of $746,752.50. Following the completion of the transaction, the chief financial officer directly owned 51,003 shares in the company, valued at approximately $6,862,453.65. The trade was a 9.81% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.46% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently issued reports on ABT. Royal Bank Of Canada lifted their price target on Abbott Laboratories from $145.00 to $147.00 and gave the company an “outperform” rating in a report on Tuesday, July 15th. Leerink Partnrs raised Abbott Laboratories to a “hold” rating in a report on Monday, June 16th. Raymond James Financial dropped their price objective on Abbott Laboratories from $142.00 to $141.00 and set an “outperform” rating for the company in a report on Friday, July 18th. Wells Fargo & Company dropped their price objective on Abbott Laboratories from $147.00 to $142.00 and set an “overweight” rating for the company in a report on Friday, July 18th. Finally, Weiss Ratings reissued a “buy (b)” rating on shares of Abbott Laboratories in a report on Wednesday. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $146.24.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.